Skip Navigation

Cardiovascular Research 2004 63(2):208-216; doi:10.1016/j.cardiores.2004.03.017
© 2004 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bogoyevitch, M. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bogoyevitch, M. A
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2004, European Society of Cardiology

An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection

Marie A Bogoyevitch*

Cell Signalling Laboratory, Biochemistry and Molecular Biology, School of Biomedical and Chemical Sciences, University of Western Australia, Australia-
Western Australian Institute for Medical Research, Australia

* Cell Signalling Laboratory, Biochemistry and Molecular Biology, School of Biomedical and Chemical Sciences, University of Western Australia, 35 Stirling Highway, Crawley, WA 6009, Australia. Tel: +61-8-6488-1348; fax: +61-8-6488-1148. Email address: marieb{at}cyllene.uwa.edu.au

Erythropoietin (Epo) was once thought to act exclusively in the formation of red blood cells. As recently reviewed by Smith et al. [Cardiovasc. Res. 59 (2003) 538–548], Epo can also act within the cardiovascular system with effects in thrombosis and hypertension as well as actions on platelets, vascular endothelium and smooth muscle, and myocytes of the heart. Here, the actions of Epo to protect neuronal cells of the brain are first evaluated and parallel actions of Epo in cardioprotection are then drawn. Thus, with recent reports of Epo receptor (EpoR) expression by cardiac myocytes, it could be predicted that Epo initiates direct protective signalling events. This is supported by five independent studies published in 2003 showing Epo protects cardiac myocytes following ischemia/reperfusion. Importantly, these protective actions have been observed in vitro and in vivo. The former suggests the direct actions of Epo to prevent myocyte death independently of its effects on red blood cell number or cells other than cardiac myocytes. The latter demonstrates the potential for Epo in the treatment of the heart post-infarction, decreasing the numbers of apoptotic myocytes, limiting infarct expansion and attenuating the post-infarct deterioration in haemodynamic function. These beneficial effects of Epo should stimulate further research into the actions of Epo.

KEYWORDS Apoptosis; Phosphatidyl inositol 3' kinase; In vitro cardioprotection; In vivo cardioprotection; Ischemia/reperfusion damage


Time for primary review 29 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Cell Physiol.Home page
D. Mihov, J. Vogel, M. Gassmann, and A. Bogdanova
Erythropoietin activates nitric oxide synthase in murine erythrocytes
Am J Physiol Cell Physiol, August 1, 2009; 297(2): C378 - C388.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
L. Li, H. Okada, G. Takemura, M. Esaki, H. Kobayashi, H. Kanamori, I. Kawamura, R. Maruyama, T. Fujiwara, H. Fujiwara, et al.
Sustained Release of Erythropoietin Using Biodegradable Gelatin Hydrogel Microspheres Persistently Improves Lower Leg Ischemia
J. Am. Coll. Cardiol., June 23, 2009; 53(25): 2378 - 2388.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
I. Hirschler-Laszkiewicz, Q. Tong, K. Conrad, W. Zhang, W. W. Flint, A. J. Barber, D. L. Barber, J. Y. Cheung, and B. A. Miller
TRPC3 Activation by Erythropoietin Is Modulated by TRPC6
J. Biol. Chem., February 13, 2009; 284(7): 4567 - 4581.
[Abstract] [Full Text] [PDF]


Home page
PhysiologyHome page
T. Rabie and H. H. Marti
Brain Protection by Erythropoietin: A Manifold Task
Physiology, October 1, 2008; 23(5): 263 - 274.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. L. Mehta
Erythropoietin in cardioprotection: does it have a future or is it all in the past?
Cardiovasc Res, September 1, 2008; 79(4): 549 - 550.
[Full Text] [PDF]


Home page
JBJSHome page
J. C. Elfar, J. A. Jacobson, J. E. Puzas, R. N. Rosier, and M. J. Zuscik
Erythropoietin Accelerates Functional Recovery After Peripheral Nerve Injury
J. Bone Joint Surg. Am., August 1, 2008; 90(8): 1644 - 1653.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
Y. Yokomaku, T. Sugimoto, S. Kume, S.-i. Araki, K. Isshiki, M. Chin-Kanasaki, M. Sakaguchi, N. Nitta, M. Haneda, D. Koya, et al.
Asialoerythropoietin Prevents Contrast-Induced Nephropathy
J. Am. Soc. Nephrol., February 1, 2008; 19(2): 321 - 328.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
A. Ramond, E. Sartorius, M. Mousseau, C. Ribuot, and M. Joyeux-Faure
Erythropoietin Pretreatment Protects Against Acute Chemotherapy Toxicity in Isolated Rat Hearts
Experimental Biology and Medicine, January 1, 2008; 233(1): 76 - 83.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. Joyeux-Faure
Cellular Protection by Erythropoietin: New Therapeutic Implications?
J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 759 - 762.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. Fandrey
A cordial affair - erythropoietin and cardioprotection
Cardiovasc Res, October 1, 2006; 72(1): 1 - 2.
[Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
X Liu, Z Zhou, X Feng, Z Jia, Y Jin, and J Xu
Cyclooxygenase-2 plays an essential part in cardioprotection of delayed phase of recombinant human erythropoietin preconditioning in rats.
Postgrad. Med. J., September 1, 2006; 82(971): 588 - 593.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
Q. Feng
Beyond erythropoiesis: The anti-inflammatory effects of erythropoietin
Cardiovasc Res, September 1, 2006; 71(4): 615 - 617.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
Y. Li, G. Takemura, H. Okada, S. Miyata, R. Maruyama, L. Li, M. Higuchi, S. Minatoguchi, T. Fujiwara, and H. Fujiwara
Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure
Cardiovasc Res, September 1, 2006; 71(4): 684 - 694.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
M Mengozzi, R Latini, M Salio, A Sfacteria, G Piedimonte, J G Gerwien, M Leist, A L Siren, P Ghezzi, and S Chimenti
Increased erythropoietin production after myocardial infarction in mice.
Heart, June 1, 2006; 92(6): 838 - 839.
[Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. Moon, M. Krawczyk, D. Paik, T. Coleman, M. Brines, M. Juhaszova, S. J. Sollott, E. G. Lakatta, and M. I. Talan
Erythropoietin, Modified to Not Stimulate Red Blood Cell Production, Retains Its Cardioprotective Properties
J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 999 - 1005.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
L. Li, G. Takemura, Y. Li, S. Miyata, M. Esaki, H. Okada, H. Kanamori, N. C. Khai, R. Maruyama, A. Ogino, et al.
Preventive Effect of Erythropoietin on Cardiac Dysfunction in Doxorubicin-Induced Cardiomyopathy
Circulation, January 31, 2006; 113(4): 535 - 543.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
T. D. Noakes, P. E. di Prampero, C. Capelli, T. Zaobornyj, L. B Valdez, A. Boveris, M. Ashenden, T. W. Secomb, S. Dufour, E. Ponsot, et al.
Comments on Point:Counterpoint "Positive effects of intermittent hypoxia (live high:train low) on exercise performance are/are not mediated primarily by augmented red cell volume"
J Appl Physiol, December 1, 2005; 99(6): 2453 - 2462.
[Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
P. T. Vlagopoulos, H. Tighiouart, D. E. Weiner, J. Griffith, D. Pettitt, D. N. Salem, A. S. Levey, and M. J. Sarnak
Anemia as a Risk Factor for Cardiovascular Disease and All-Cause Mortality in Diabetes: The Impact of Chronic Kidney Disease
J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3403 - 3410.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. C. Kovacic
Further Aspects of Anemia, Heart Failure, and Erythropoietin
J. Am. Coll. Cardiol., May 3, 2005; 45(9): 1549 - 1550.
[Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
F. Fiordaliso, S. Chimenti, L. Staszewsky, A. Bai, E. Carlo, I. Cuccovillo, M. Doni, M. Mengozzi, R. Tonelli, P. Ghezzi, et al.
A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury
PNAS, February 8, 2005; 102(6): 2046 - 2051.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.